drugset

drugset / Trial / NCT00224133

The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months

NCT00224133 ↗

Phase 3 Completed 661 enrolled Watson Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.

Timeline

Start: 2005-09
Primary completion: 2007-04
Completion: 2007-04

Publications

Results Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology. 2009 Dec;74(6):1318-22. doi: 10.1016/j.urology.2009.06.072. Epub 2009 Oct 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Silodosin	Unknown	8 mg	—

Indications